The present research aimed to improve the effectiveness of TB treatment by a non conventional therapy and using teh respiratory tract as a novel adminictration route for rifampicin. The study dealt with the design of Solid Lipid Microparticles (SLM) to be delivered by a Dry Powder Inhaler (DPI) device and to target the alveolar macrophages. The negligible in vitro drug release indicated the capacity of the matrix to firmly entrap the drug. Rifampicin maintained its biological activity during the preparation steps. Moreover, SLM were suitable to be taken up by murine J774 cells.
Inhalated drug delivery systems to target alveolar macrophages for tuberculosis therapy: design of safe SLM loaded with rifampicin / Maretti, Eleonora; Iannuccelli, Valentina; Leo, Eliana Grazia; Bondi, Moreno; Croce, Maria Antonietta; Sacchetti, Francesca; Rossi, Tiziana. - STAMPA. - ND:(2013), pp. 6-6. (Intervento presentato al convegno 6° Congresso Nazionale SIF. Il ruolo della ricerca farmacologica per la crescita e la salute in Italia tenutosi a Torino nel 23-26 ottobre 2013).
Inhalated drug delivery systems to target alveolar macrophages for tuberculosis therapy: design of safe SLM loaded with rifampicin
MARETTI, ELEONORA;IANNUCCELLI, Valentina;LEO, Eliana Grazia;BONDI, Moreno;CROCE, Maria Antonietta;SACCHETTI, FRANCESCA;ROSSI, Tiziana
2013
Abstract
The present research aimed to improve the effectiveness of TB treatment by a non conventional therapy and using teh respiratory tract as a novel adminictration route for rifampicin. The study dealt with the design of Solid Lipid Microparticles (SLM) to be delivered by a Dry Powder Inhaler (DPI) device and to target the alveolar macrophages. The negligible in vitro drug release indicated the capacity of the matrix to firmly entrap the drug. Rifampicin maintained its biological activity during the preparation steps. Moreover, SLM were suitable to be taken up by murine J774 cells.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
